| 摘要 |
The present application pertains to a composition comprising monoclonal antibodies directed against a circulating proinflammatory cytokine, said antibodies having a strong affinity for the receptor FcyRIIIa (CD16), in particular the fucose level of all antibodies of said composition being less than 60%, preferably less than 50%, and in particular, the galactosylation level of all antibodies of said composition being at least 60%, for the use thereof in the context of preventing or treating early phases of inflammation. The present application also pertains to a composition comprising monoclonal antibodies directed against a circulating bacterial toxin, having an improved affinity for the receptor FcyRIIIa (CD16) compared to antibodies directed against said bacterial toxin, produced in the CHO cell line, for the use thereof in the context of preventing or treating early phases of a bacterial infection related to the release of said toxin. |
